Correction to: Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes

[1]  N. Snir,et al.  Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug , 2018, Rheumatology.

[2]  R. Terkeltaub,et al.  Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal Deposition , 2018, Arthritis & rheumatology.

[3]  C. Müller,et al.  Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. , 2017, MedChemComm.

[4]  C. Müller,et al.  Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors , 2017, Front. Pharmacol..

[5]  Piet Herdewijn,et al.  Thiazolo[3,2-a]benzimidazol-3(2H)-one derivatives: Structure-activity relationships of selective nucleotide pyrophosphatase/phosphodiesterase1 (NPP1) inhibitors. , 2016, Bioorganic & medicinal chemistry.

[6]  Hak-Sung Kim,et al.  Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. , 2015, Angewandte Chemie.

[7]  J. Sévigny,et al.  Synthesis and structure-activity relationship of uracil nucleotide derivatives towards the identification of human P2Y6 receptor antagonists. , 2015, Bioorganic & medicinal chemistry.

[8]  P. Lagüe,et al.  Quinazoline‐4‐piperidine sulfamides are specific inhibitors of human NPP1 and prevent pathological mineralization of valve interstitial cells , 2015, British journal of pharmacology.

[9]  C. Müller,et al.  α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors. , 2015, Journal of medicinal chemistry.

[10]  Marie-Chloé Boulanger,et al.  Adenosine derived from ecto-nucleotidases in calcific aortic valve disease promotes mineralization through A2a adenosine receptor. , 2015, Cardiovascular research.

[11]  C. Müller,et al.  Polyoxometalates--potent and selective ecto-nucleotidase inhibitors. , 2015, Biochemical pharmacology.

[12]  C. Müller,et al.  Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1). , 2014, Journal of medicinal chemistry.

[13]  H. Senderowitz,et al.  Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold. , 2014, Journal of medicinal chemistry.

[14]  C. Müller,et al.  Large‐volume sample stacking with polarity switching for monitoring of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) reactions by capillary electrophoresis , 2014, Electrophoresis.

[15]  H. Zimmermann,et al.  A new, sensitive ecto-5'-nucleotidase assay for compound screening. , 2014, Analytical biochemistry.

[16]  H. Senderowitz,et al.  Nonhydrolyzable ATP analogues as selective inhibitors of human NPP1: a combined computational/experimental study. , 2013, Journal of medicinal chemistry.

[17]  B. Fischer,et al.  Characterization of complexes of nucleoside-5'-phosphorothioate analogues with zinc ions. , 2013, Inorganic chemistry.

[18]  N. Sträter,et al.  Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.

[19]  G. Dubyak,et al.  Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. , 2011, American journal of physiology. Heart and circulatory physiology.

[20]  G. Reiser,et al.  Diadenosine 5',5''-(boranated)polyphosphonate analogues as selective nucleotide pyrophosphatase/phosphodiesterase inhibitors. , 2010, Journal of medicinal chemistry.

[21]  J. Bajorath,et al.  Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. , 2010, Journal of medicinal chemistry.

[22]  K. Khan,et al.  1,3,4-Oxadiazole-2(3H)-thione and its analogues: a new class of non-competitive nucleotide pyrophosphatases/phosphodiesterases 1 inhibitors. , 2009, Bioorganic & medicinal chemistry.

[23]  A. Cheng,et al.  Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design. , 2009, Bioorganic & medicinal chemistry letters.

[24]  J. Schrader,et al.  Distribution of ectonucleotidases in the rodent brain revisited , 2008, Cell and Tissue Research.

[25]  C. Müller,et al.  A highly sensitive CE‐UV method with dynamic coating of silica‐fused capillaries for monitoring of nucleotide pyrophosphatase/phosphodiesterase reactions , 2008, Electrophoresis.

[26]  Chia-Yun Chen,et al.  Comparative adsorption of Cu(II), Zn(II), and Pb(II) ions in aqueous solution on the crosslinked chitosan with epichlorohydrin. , 2008, Journal of hazardous materials.

[27]  C. R. Fürstenau,et al.  Kinetic and biochemical characterization of an ecto-nucleotide pyrophosphatase/phosphodiesterase (EC 3.1.4.1) in cells cultured from submandibular salivary glands of rats. , 2007, Archives of oral biology.

[28]  C. Müller,et al.  Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[29]  Atta-ur-rahman,et al.  New biscoumarin derivatives-cytotoxicity and enzyme inhibitory activities. , 2006, Bioorganic & medicinal chemistry.

[30]  M. Bollen,et al.  NPP-type ectophosphodiesterases: unity in diversity. , 2005, Trends in biochemical sciences.

[31]  K. Kikuchi,et al.  Inhibition of Autotaxin by Lysophosphatidic Acid and Sphingosine 1-Phosphate* , 2005, Journal of Biological Chemistry.

[32]  F. Aloisi,et al.  ATP regulates oligodendrocyte progenitor migration, proliferation, and differentiation: involvement of metabotropic P2 receptors , 2005, Brain Research Reviews.

[33]  K. Sano,et al.  Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases. , 2003, European journal of biochemistry.

[34]  J. Goding,et al.  Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. , 2003, Biochimica et biophysica acta.

[35]  J. Boeynaems,et al.  Involvement of P2Y receptors in the differentiation of haematopoietic cells , 2003, Journal of leukocyte biology.

[36]  H. Iwasaki,et al.  Cartilage intermediate layer protein expression in calcium pyrophosphate dihydrate crystal deposition disease. , 2002, The Journal of rheumatology.

[37]  G. Burnstock.  Purinergic Signaling and Vascular Cell Proliferation and Death , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[38]  R. Terkeltaub.  Inorganic pyrophosphate generation and disposition in pathophysiology. , 2001, American journal of physiology. Cell physiology.

[39]  R. Terkeltaub,et al.  Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. , 2001, Arthritis and rheumatism.

[40]  H. Zimmermann.  Extracellular metabolism of ATP and other nucleotides , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[41]  B. Fischer,et al.  Novel inhibitors of nucleoside triphosphate diphosphohydrolases: chemical synthesis and biochemical and pharmacological characterizations. , 2000, Journal of medicinal chemistry.

[42]  D. Roymans,et al.  Ecto‐nucleotide pyrophosphatase modulates the purinoceptor‐mediated signal transduction and is inhibited by purinoceptor antagonists , 2000, British journal of pharmacology.

[43]  M. Bollen,et al.  Nucleotide Pyrophosphatases/Phosphodiesterases on the Move , 2000, Critical reviews in biochemistry and molecular biology.

[44]  S. Hoshino,et al.  Inhibition of phosphodiesterase/pyrophosphatase activity of PC-1 by its association with glycosaminoglycans. , 1999, European journal of biochemistry.

[45]  R. Terkeltaub,et al.  Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. , 1999, Arthritis and rheumatism.

[46]  Ying Chen,et al.  Matrix Vesicle Plasma Cell Membrane Glycoprotein‐1 Regulates Mineralization by Murine Osteoblastic MC3T3 Cells , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[47]  M. Bollen,et al.  Threonine autophosphorylation and nucleotidylation of the hepatic membrane protein PC-1. , 1996, European journal of biochemistry.

[48]  R. Terkeltaub,et al.  Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. Regulation of PC-1 expression in osteosarcoma cells by transforming growth factor-beta. , 1994, The Journal of clinical investigation.

[49]  Rachow Jw,et al.  Inorganic pyrophosphate metabolism in arthritis. , 1988 .

[50]  A. Baykov,et al.  A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. , 1988, Analytical biochemistry.

[51]  H. Schumacher,et al.  Synovial fluid crystals in osteoarthritis. , 1985, Arthritis and rheumatism.

[52]  A. Bjelle,et al.  An ultrastructural study of the articular cartilage in calcium pyrophosphate dihydrate (CPPD) crystal deposition disease (Chondrocalcinosis Articularis) , 1975, Calcified Tissue Research.

[53]  C. R. Fürstenau,et al.  The effects of angiotensin II and genetic hypertension upon extracellular nucleotide hydrolysis by rat platelet ectoenzymes. , 2007, Thrombosis research.

[54]  H. Schumacher,et al.  Synovial fluid features and their relations to osteoarthritis severity: new findings from sequential studies. , 2003, Osteoarthritis and cartilage.

[55]  G Burnstock,et al.  Potential therapeutic targets in the rapidly expanding field of purinergic signalling. , 2002, Clinical medicine.